Janssen Research & Development, Llc

This study tests a new drug called talquetamab for people with multiple myeloma that has come back or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects in abou…

This large Phase 3 study tests whether a daily oral medication called milvexian can lower the chance of having another stroke in people who recently had a mild stroke or a high-risk mini-stroke. Over 12,500 participants are randomly assigned to receive either milvexian or a place…

This early-stage study tests a combination of two types of immune-based drugs (bispecific antibodies and a checkpoint inhibitor) in people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find safe doses and understand side effects.…

This early-stage study tests a new drug called bleximenib combined with standard leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 part…

This study tests a drug combination (daratumumab plus chemotherapy) in people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. It focuses on heart safety and how the drug works in different racial groups. About 151 participants will …

This study tests an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for 12 weeks, and doctors m…

This early-stage study tests combinations of daratumumab (a targeted antibody) with two other drugs (talquetamab and teclistamab) in 290 adults with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. Part…

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo (inactive pill), or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal…

This study tests an experimental drug called JNJ-63723283, which helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others. The goal is to find the best dose and see if the drug can shrink tumors. About 413 participants …

This study tests a drug called erdafitinib against standard treatments (chemotherapy or pembrolizumab) in people with advanced bladder cancer that has specific FGFR gene changes. The goal is to see if erdafitinib helps people live longer. About 629 adults whose cancer worsened af…

This program offers early access to TAR-200, an experimental treatment, for people with high-risk non-muscle invasive bladder cancer who have run out of standard options. Participants must have tried all other treatments and cannot join a clinical trial. The goal is to provide tr…

This study tests a combination of two drugs (talquetamab and teclistamab) that help the immune system attack myeloma cells. It involves 228 adults with relapsed or refractory multiple myeloma, including those with tumors outside the bone marrow. The goal is to find the best dose,…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to 18 with Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a previous ustekinumab study and shown benefit from the drug. The main goal is to m…

This study tests a drug called guselkumab for children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. About 120 participants receive either the study drug, a placebo, or an active comparator to see how well it clears the skin …

This study tests whether the drug daratumumab can delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. About 390 people with high-risk smoldering myeloma received either daratumumab injections or were simply monitored. The goal is to see if the …

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a specific type of advanced lung cancer (EGFR exon 20 insertion mutation) live longer without their cancer growing. About 308 adults with non-small cell lung cancer that has spread wil…

This early-stage study tests a drug called apalutamide in 19 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check how the drug moves through the body and to see if it is safe. Researchers will also me…

This study tests an experimental drug called JNJ-77242113 for people with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. About 684 adults will receive either the drug or a placebo to see if it clears or greatly improves their skin. The trial als…

This study looks at men with metastatic prostate cancer that still responds to hormone therapy. After 6 months of standard treatment, some men will take breaks from the hormone therapy to see if it reduces hot flashes without allowing the cancer to grow back faster. The goal is t…

This early-stage study tests a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug is an antibody carrying a radioactive payload that targets a protein found on prostate cancer cells.…

This study looks at whether special skin care can lower the chance of bad rashes and other skin problems in people with advanced lung cancer who are taking two drugs (amivantamab and lazertinib). About 305 patients will be assigned to different skin care routines to see which wor…

This study tests whether guselkumab, a targeted injectable drug, can reduce joint pain and swelling in people with active psoriatic arthritis who did not get enough relief from or could not tolerate a common first-line treatment (anti-TNF therapy). About 450 adults with active di…

This study tests a drug called guselkumab in 350 people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if it can reduce symptoms and heal the gut lining. Participants receive either the drug or a placebo, and researchers…

This early-stage study tests a new drug called amivantamab, alone or with other treatments, in people with advanced non-small cell lung cancer that has spread or cannot be removed. The goal is to find safe doses and see if the drug shrinks tumors. About 751 participants are invol…

This study tests a drug called golimumab in 84 children with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (fewer symptoms) within 6 weeks and m…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) helps people with untreated multiple myeloma achieve deeper cancer remission. About 395 participants who are not eligible for a stem cell transplant …

This early-phase study tests a new drug called JNJ-88998377 in about 58 people with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will be cl…

This study tests a drug called erdafitinib, which targets specific gene changes in cancer cells, for people with advanced bladder cancer that has spread. It involves about 125 participants and looks at safety and how well the tumor shrinks when erdafitinib is used alone or with o…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The goal is to see if the drug reduces joint pain, swelling, and skin symptoms better than a placebo. Participants …

This study tests a drug called apalutamide in Chinese men with a type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread yet. The goal is to see if the drug can delay a rise in PSA levels, a key sign of cancer progression, compared to a p…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) live longer without the cancer growing. The study includes 776 adults wh…

This study tests whether a combination of two drugs, amivantamab and lazertinib, works better than the standard drug osimertinib for people with advanced non-small cell lung cancer that has certain EGFR gene mutations. About 1,074 participants who have not had prior treatment wil…

This study compares a new oral blood thinner, milvexian, to the standard drug apixaban in about 20,000 adults with atrial fibrillation (an irregular heartbeat). The goal is to see if milvexian is at least as good at preventing strokes and blood clots, while also checking for blee…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This study tests two experimental treatments—TAR-200 (a drug placed directly into the bladder) and cetrelimab (an immunotherapy injection)—alone or together in 220 people with high-risk bladder cancer that did not get better after standard BCG therapy. Participants are those who …

This study tests two different doses of an experimental drug called erdafitinib in people with advanced bladder cancer that has spread or cannot be removed by surgery and has certain FGFR gene changes. The main goal is to see how well the drug shrinks tumors. About 239 participan…

This early-stage study tests a new drug combination (JNJ-80948543 plus JNJ-75348780) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safest dose an…

This study tests a drug called guselkumab in over 1,000 people with active psoriatic arthritis (PsA). The goal is to see if it reduces pain, swelling, and slows joint damage compared to a placebo. Participants receive injections under the skin, and the study is in its final phase…

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 adults who haven't responded well to other advanced treatments will take part. The main goal is to see if t…

This study tests a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma, a type of blood cancer. The goal is to see if it can make cancer undetectable in the bone marrow (called minimal residual disease negative). About 210 adults who have alr…

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy for adults with chronic lymphocytic leukemia (CLL) who are older or have other health issues. About 211 participants will receive either …

This study tests an experimental drug called M281 in adults with warm autoimmune hemolytic anemia, a condition where the immune system mistakenly destroys red blood cells, causing fatigue and anemia. The trial involves 118 participants and aims to see if M281 can improve hemoglob…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug or a placebo alongside hormone therapy. The goal is…

This study tests whether adding daratumumab to the standard maintenance drug lenalidomide can clear remaining cancer cells in people with multiple myeloma who still have traces of disease after a stem cell transplant. About 200 participants will receive either the combination or …

This study tests a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a targeted drug)—in people with high-risk multiple myeloma that has not responded well to prior therapies. The main goal is to check safety, and researchers will also measure how many pat…

This study tests two treatments for people with a certain type of bladder cancer that has grown into the muscle wall. Participants will get either a drug placed directly into the bladder (TAR-200) plus an immunotherapy injection (cetrelimab), or the injection alone, before their …

This study tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease, an autoimmune condition causing dry eyes, dry mouth, and other symptoms. About 655 participants receive either the drug or a placebo for 48 weeks. The main…

This study tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes are participating. The main goal is to s…

This early-stage study tests a combination of two drugs, amivantamab and docetaxel, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo can shrink tumors. About 12 participants will take part, and the study fo…

This study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. About 24 adults and children who already received treatment in one eye will get the therapy in their other eye. Researchers will chec…

This study tests niraparib combined with other drugs in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to find safe, effective doses that can shrink tumors or lower cancer markers. 136 participants a…

This study tests two medications, ustekinumab and guselkumab, in 50 children with active juvenile psoriatic arthritis. The goal is to see how well the drugs control joint swelling and pain, and how safe they are. Participants receive injections and are monitored for about a year.

This study tests a drug called nipocalimab against a placebo in 36 people with active myositis, a condition causing muscle inflammation and weakness. The goal is to see if nipocalimab can improve muscle strength and reduce disease activity while allowing lower steroid use. Partic…

This early-stage study tests the safety and best dose of talquetamab when combined with other cancer drugs for people with multiple myeloma, a type of blood cancer. About 166 participants will receive different drug combinations to see how well they tolerate the treatment and wha…

This early-stage study tests a new drug called ARX517, alone or with other prostate cancer treatments, in 183 men with metastatic prostate cancer that has spread. The main goal is to check the drug's safety and find the best dose. Participants must have prostate cancer that hasn'…

This study tests whether a new way of making teclistamab works as well as the current version in people with multiple myeloma that has come back or not responded to treatment. About 108 participants will receive either the old or new version of the drug to compare how the body pr…

This early-stage study tests a new drug called JNJ-78278343 for men with advanced prostate cancer that has spread. The drug works by redirecting the body's immune T-cells to attack cancer cells. The main goals are to find the safest dose and check for side effects in 216 particip…

This study tests whether a single infusion of cilta-cel (a CAR-T therapy that targets cancer cells) works better than standard maintenance drugs for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive initial ch…

This early-stage study tests a new drug, teclistamab, in 302 people with multiple myeloma that has come back or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects…

This program offered early access to talquetamab, an investigational drug, for people with multiple myeloma that had stopped responding to other treatments. It was designed for patients who had no other options and whose doctors requested the drug on their behalf. The program is …

This study tests a drug called guselkumab in people with active psoriatic arthritis that also causes spine pain and stiffness. About 411 participants will receive either the drug or a placebo to see if it reduces symptoms and inflammation. The goal is to improve daily life by tar…

This phase 3 study compares a new combination of two drugs (teclistamab and daratumumab) against two standard three-drug combinations for people with multiple myeloma that has come back or stopped responding to prior treatments. About 587 participants will be randomly assigned to…

This study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either cannot have or choose not to have their bladder removed. The study compares TAR-200 to standard chemotherapy placed …

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo shrinks tumors. About 71 participants are enrolled, and the study tracks side effect…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and sores. The goal is to see if the drug can reduce symptoms and lead to remission. About 112 children will receive the drug, …

This study is testing whether two new treatments work better than the current standard therapy for high-risk bladder cancer that hasn't spread into the muscle wall. Researchers are comparing a new drug delivery system called TAR-200 (with or without an immunotherapy drug called c…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.